RxDoctor Payments Data

Robert Wrona, DO

Family Medicine · Orland Park, ILNPI 1841244043

Payments from drug & device makers

$16,895in general payments, 2019–2025

Across 974 payments — averaging $17.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Boehringer Ingelheim$2K
  • AbbVie$1K
  • Lilly USA, LLC$1K
  • Novo Nordisk$1K
  • Amgen$1K
  • plus $8K from 46 others

What the payments were for

  • Food & beverage$16,872100%
  • Education$230%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,895 in reported general payments places this provider in the 95th percentile of 4,116 family medicine providers in Illinois.

See all family medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$200,715
Medicare patients
473
Services billed
2,612

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban128$151,023
OzempicSemaglutide61$88,494
MounjaroTirzepatide65$74,664
JardianceEmpagliflozin49$65,088
JanuviaSitagliptin Phosphate28$39,466
XareltoRivaroxaban22$23,737
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$15,225
NexlizetBempedoic Acid/Ezetimibe15$12,550
Repatha SyringeEvolocumab12$10,985
Mesalamine19$8,088
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog11$8,076
Atorvastatin Calcium672$6,935
Lantus SolostarInsulin Glargine,hum.Rec.Anlog29$6,308
Fluticasone-SalmeterolFluticasone Propion/Salmeterol27$5,536
Levothyroxine Sodium437$5,399

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$455$151,023128 claims
Novo NordiskOzempic$1,169$88,49461 claims
Lilly USA, LLCMounjaro$1,221$74,66465 claims
Boehringer IngelheimJardiance$1,677$65,08849 claims
MerckJanuvia$454$39,46628 claims
Johnson & JohnsonXarelto$975$23,73722 claims
GSKTrelegy Ellipta$496$15,22512 claims
Esperion Therapeutics, Inc.Nexlizet$341$12,55015 claims
AbbVieSynthroid$1,274$1,61850 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,116 family medicine providers in Illinois.

Other family medicine in Orland Park

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →